Cargando…

Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV‐Coinfected Children in India: Recommendations for Dose Modifications

This work aimed to evaluate the once‐daily antituberculosis treatment as recommended by the new Indian pediatric guidelines. Isoniazid, rifampin, and pyrazinamide concentration–time profiles and treatment outcome were obtained from 161 Indian children with drug‐sensitive tuberculosis undergoing thri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guiastrennec, Benjamin, Ramachandran, Geetha, Karlsson, Mats O., Kumar, A.K. Hemanth, Bhavani, Perumal Kannabiran, Gangadevi, N. Poorana, Swaminathan, Soumya, Gupta, Amita, Dooley, Kelly E., Savic, Radojka M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004234/ https://www.ncbi.nlm.nih.gov/pubmed/29247506 http://dx.doi.org/10.1002/cpt.987

Ejemplares similares

Dyslipidaemia Among Children Living with HIV after 48 Weeks of First-line Antiretroviral Therapy
por: Perumal Kannabiran, Bhavani, et al.
Publicado: (2017)

Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2019)

Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients
por: Ramachandran, Geetha, et al.
Publicado: (2013)

Can Urine Lamivudine Be Used to Monitor Antiretroviral Treatment Adherence?
por: Kumar, Agibothu K Hemanth, et al.
Publicado: (2006)

Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients
por: Kumar, A. K. Hemanth, et al.
Publicado: (2018)

Role of pharmacogenomics in the treatment of tuberculosis: a review
por: Ramachandran, Geetha, et al.
Publicado: (2012)

Clinical impact of plasma concentrations of first-line antituberculosis drugs
por: Perumal, R, et al.
Publicado: (2023)

First case of pulmonary tuberculosis and visceral leishmaniasis coinfection successfully treated with antituberculosis drug and liposomal amphotericin B
por: Hasnain, Md Golam, et al.
Publicado: (2014)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs
por: Kumar, Agibothu Kupparam Hemanth, et al.
Publicado: (2017)

N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis
por: Hemanth Kumar, A. K., et al.
Publicado: (2017)

Application of population pharmacokinetics to cladribine
por: Lindemalm, Synnöve, et al.
Publicado: (2005)

Standard Error of Empirical Bayes Estimate in NONMEM® VI
por: Kang, Dongwoo, et al.
Publicado: (2012)

Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests
por: Swaminathan, Soumya, et al.
Publicado: (2016)

Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology
por: Dooley, Kelly E., et al.
Publicado: (2019)

Acquired Resistance to Antituberculosis Drugs
por: Aung, Htin Lin, et al.
Publicado: (2018)

Antiviral Therapy with Entecavir following Antituberculosis Therapy Alleviates Liver Injury and Restores Innate Immunity in Tuberculosis Patients Coinfected with Hepatitis B Virus
por: Huang, Xiaojing, et al.
Publicado: (2021)

Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study
por: Ramachandran, Geetha, et al.
Publicado: (2023)

Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons
por: Gupta, Amita, et al.
Publicado: (2019)

Retracted: Antiviral Therapy with Entecavir following Antituberculosis Therapy Alleviates Liver Injury and Restores Innate Immunity in Tuberculosis Patients Coinfected with Hepatitis B Virus
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Antituberculosis drug-induced hepatotoxicity in children
por: Donald, Peter R
Publicado: (2011)

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
por: Salinger, David H., et al.
Publicado: (2019)

Diagnosis of Hypersensitivity Induced by Antituberculosis Drugs
por: Wu, Yuqing, et al.
Publicado: (2021)

Model‐Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans
por: Guiastrennec, Benjamin, et al.
Publicado: (2018)

Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs
por: Ernest, Jacqueline P., et al.
Publicado: (2023)

Dyslipidemia among HIV-infected Patients with Tuberculosis Taking Once-daily Nonnucleoside Reverse-Transcriptase Inhibitor–Based Antiretroviral Therapy in India
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2011)

Mycobacterium tuberculosis resistance to antituberculosis drugs in Mozambique,
por: Pires, Germano Manuel, et al.
Publicado: (2014)

The impact of immune disturbances on the failure of antituberculosis treatment
por: LESNIC, EVELINA, et al.
Publicado: (2016)

Empyema Necessitans due to Interruption of Antituberculosis Treatment
por: Benaragama, H. N., et al.
Publicado: (2019)

A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug–Drug Interactions With Antiretroviral and Antituberculosis Treatment
por: Francis, Jose, et al.
Publicado: (2021)

Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis
por: Gafar, Fajri, et al.
Publicado: (2023)

High-Dose Rifampicin Mediated Systemic Alterations of Cytokines, Chemokines, Growth Factors, Microbial Translocation Markers, and Acute-Phase Proteins in Pulmonary Tuberculosis
por: Kathamuthu, Gokul Raj, et al.
Publicado: (2022)

The Effect of an Antituberculosis Serum on the Development of Experimental Tuberculosis of the Skin
por: Thomas, Robert M., et al.
Publicado: (1940)

Barriers to Initiation of Antiretrovirals during Antituberculosis Therapy in Africa
por: Pepper, Dominique J., et al.
Publicado: (2011)

The Chemical Components of Sesbania grandiflora Root and Their Antituberculosis Activity
por: Hasan, Noviany, et al.
Publicado: (2012)

Antituberculosis: Synthesis and Antimycobacterial Activity of Novel Benzimidazole Derivatives
por: Keng Yoon, Yeong, et al.
Publicado: (2013)

Adverse Reactions to Antituberculosis Drugs in Iranian Tuberculosis Patients
por: Farazi, Aliasghar, et al.
Publicado: (2014)

Risk factors associated with adverse reactions to antituberculosis drugs
por: Resende, Laíse Soares Oliveira, et al.
Publicado: (2015)

The role of exogenous risk factors of antituberculosis treatment failure
por: LESNIC, EVELINA, et al.
Publicado: (2016)

Seizures following Intoxication with a Common Antituberculosis Drug
por: Lahlou, Adnane, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_74i98r5c2rbj02p5dpa0qq3s1u